{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:23:37Z","timestamp":1791829417324,"version":"4.3.4"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Soluble suppression of tumorigenicity-2 (sST2) is a promising biomarker of cardiovascular disease and heart failure. Data about the changes in sST2 concentrations during cancer treatment and the relationship with cancer treatment-related cardiotoxicity are sparse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis to explore longitudinal changes in sST2 levels at three time points (T0 baseline, T1 post-chemotherapy, and T2 follow-up) in cancer patients treated with cardiotoxic therapies and compared these changes to traditional biomarkers of cardiac injury, i.e., troponin and NT-proBNP. Using random-effects models, mean differences (MD), and standardized MD (SMD), we analyzed (i) ST2 longitudinal changes, (ii) the association between ST2 and cardiotoxicity [defined through left ventricular ejection fraction (LVEF)] providing pooled estimates of correlations, and (iii) the SMD variations among biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight studies were included, comprising 433 patients treated with anthracycline and\/or HER2-directed antibodies. There was a trend toward increased sST2 levels from T0 to T2 (MD 1.86, 95% CI \u22120.97 to 4.68,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.200) and decreased levels from T1 to T2 (MD \u22121.96, 95% CI \u22124.28 to 0.37,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.100). A pooled analysis showed a negative correlation between sST2 levels and LVEF (r \u22120.29, 95% CI, \u22120.49- \u22120.05,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.010). Comparisons with Troponin and NT-proBNP showed a significantly higher Troponin SMD at T0-T1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027), while no significant differences were observed for NT-proBNP.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>sST2 showed dynamic changes during cardiotoxic therapy correlating with cardiotoxicity. Troponin was demonstrated to have greater longitudinal variations. Further research is needed to evaluate longitudinal sST2 levels in patients who develop cardiotoxicity vs. those who do not.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1624023","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:08:06Z","timestamp":1762866486000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Soluble suppression of tumorigenicity-2 changes during cardiotoxic cancer treatment: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Luca","family":"Fazzini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Angius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pascalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Deidda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano Maria","family":"Pugliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Quagliariello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Maurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ameri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Cadeddu Dessalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC: CardioOncology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy\u2013related cardiac dysfunction and heart failure","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","article-title":"American society of clinical oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects","volume":"25","author":"Carver","year":"2007","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the European society of cardiology in collaboration with the international cardio-oncology society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/eurheartj\/ehae496","article-title":"Anthracycline-induced cardiovascular toxicity: validation of the heart failure association and international cardio-oncology society risk score","volume":"46","author":"Rivero-Santana","year":"2024","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2459\/JCM.0000000000001589","article-title":"The added value of the HFA\/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer","volume":"25","author":"Di Lisi","year":"2024","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American heart association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ijcard.2009.09.564","article-title":"Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide","volume":"148","author":"Feola","year":"2011","journal-title":"Int J Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/CIRCRESAHA.118.312706","article-title":"Established and emerging roles of biomarkers in heart failure","volume":"123","author":"Ibrahim","year":"2018","journal-title":"Circ Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","article-title":"Biomarkers for the diagnosis and management of heart failure","volume":"27","author":"Castiglione","year":"2022","journal-title":"Heart Fail Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s11897-024-00687-5","article-title":"Genetic biomarkers in heart failure: from gene panels to polygenic risk scores","volume":"21","author":"Figueiral","year":"2024","journal-title":"Curr Heart Fail Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jchf.2016.09.010","article-title":"Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis","volume":"5","author":"Aimo","year":"2017","journal-title":"JACC Heart Fail"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e005582","DOI":"10.1161\/CIRCHEARTFAILURE.118.005582","article-title":"ST2 In heart failure","volume":"11","author":"Bay\u00e9s-Genis","year":"2018","journal-title":"Circ Heart Fail"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.3390\/jcm12123970","article-title":"Prognostic value of sST2 in heart failure","volume":"12","author":"Sciatti","year":"2023","journal-title":"J Clin Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"Br Med J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"B21","first-page":"3","article-title":"On the \u201cprobable error\u201d of a coefficient of correlation deduced from a small sample","volume":"1","author":"Fisher","year":"1921","journal-title":"Metron"},{"key":"B22","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024)","author":"Higgins","year":"2024"},{"key":"B23","doi-asserted-by":"publisher","first-page":"64b","DOI":"10.1016\/j.amjcard.2015.01.043","article-title":"ST2 And patient prognosis in chronic heart failure","volume":"115","author":"Bayes-Genis","year":"2015","journal-title":"Am J Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cca.2014.09.021","article-title":"Soluble ST2 in heart failure","volume":"443","author":"Dieplinger","year":"2015","journal-title":"Clin Chim Acta"},{"key":"B25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/eurjhf\/hfs006","article-title":"Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology","volume":"14","author":"Broch","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"B26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s11596-024-2907-x","article-title":"Soluble ST2: a novel biomarker for diagnosis and prognosis of cardiovascular disease","volume":"44","author":"Feng","year":"2024","journal-title":"Curr Med Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3390\/jpm13121710","article-title":"Biomarkers and strain echocardiography for the detection of subclinical cardiotoxicity in breast cancer patients receiving anthracyclines","volume":"13","author":"Bhagat","year":"2023","journal-title":"J Pers Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40959-023-00174-1","article-title":"Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy\u2014a prospective analysis","volume":"9","author":"Dean","year":"2023","journal-title":"Cardiooncology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"oyae299","DOI":"10.1093\/oncolo\/oyae299","article-title":"Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1\/2 mutation: the BRCAN study","volume":"30","author":"Cort\u00e9s-Salgado","year":"2024","journal-title":"Oncologist"},{"key":"B31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12885-018-4015-4","article-title":"Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients","volume":"18","author":"Fr\u00e8res","year":"2018","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e029574","DOI":"10.1161\/JAHA.123.029574","article-title":"Circulating cardiovascular biomarkers in cancer therapeutics-related cardiotoxicity: review of critical challenges, solutions, and future directions","volume":"12","author":"Murtagh","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"B33","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/eurjpc\/zwaa034","article-title":"Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry","volume":"29","author":"Caro-Cod\u00f3n","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"6745","DOI":"10.3390\/jcm11226745","article-title":"Metabolomic profiles on antiblastic cardiotoxicity: new perspectives for early diagnosis and cardioprotection","volume":"11","author":"Fazzini","year":"2022","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.3390\/jcm14041286","article-title":"Genetic background in patients with cancer therapy-induced cardiomyopathy","volume":"14","author":"Fazzini","year":"2025","journal-title":"J Clin Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/cancers15010207","article-title":"Evaluating cardiotoxicity in breast cancer patients treated with HER2 inhibitors: could a combination of radionuclide ventriculography and cardiac biomarkers predict the cardiac impact?","volume":"15","author":"Gherghe","year":"2022","journal-title":"Cancers"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e12447","DOI":"10.1097\/MD.0000000000012447","article-title":"Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy","volume":"97","author":"Huang","year":"2018","journal-title":"Medicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/00045632221131672","article-title":"Assessing the cardiotoxicity of epirubicin-based chemotherapy in patients with breast cancer using high-sensitivity cardiac troponin T, N-terminal pro b-type natriuretic peptide and soluble suppression of tumorigenicity-2","volume":"59","author":"Isemede","year":"2022","journal-title":"Ann Clin Biochem"},{"key":"B40","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1159\/000525683","article-title":"Diagnostic value of sST2, VCAM-1, and adiponectin in patients with breast cancer to predict anti-tumour treatment-related cardiac events: a pilot study","volume":"45","author":"Rosenkaimer","year":"2022","journal-title":"Oncol Res Treat"},{"key":"B41","first-page":"68","article-title":"Efficacy of novel cardiac biomarkers in detecting anthracycline-induced cardiac toxicity","volume":"15","author":"Shirzadi","year":"2021","journal-title":"Int Cardiovasc Res J"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1624023\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:08:07Z","timestamp":1762866487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1624023\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":41,"alternative-id":["10.3389\/fcvm.2025.1624023"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1624023","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"article-number":"1624023"}}